CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy | Genetic Testing for Mitochondrial Disorders

Defines medical necessity criteria, prior authorization requirements, and coverage for Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (CPT 0417U) for Medicare Advantage and commercial products, including criteria for targeted familial variant testing in at-risk relatives.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy | Genetic Testing for Mitochondrial Disorders

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2023

Next Review Date

Key ActionObtain prior authorization (required for Medicare Advantage; recommended for Commercial) for Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (CPT 0417U) and ensure the ordering physician handles authorization and appeals.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes

1Covered PLA test

0417UEffective code date

Coverage Summary

Defines medical necessity criteria, prior authorization requirements, and coverage for Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (CPT 0417U). Policy stance: Covered with criteria. Effective date: 2023-10-01. Last review: 2023-09-06.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Diagnostic yield for NGS panels: reported rates of approximately 15% to 25% in studies.

Conclusion on clinical utility: evidence is sufficient to determine testing improves net health outcome for symptomatic individuals and for targeted familial testing in at-risk relatives; testing can confirm diagnosis, often avoid muscle biopsy, and inform reproductive decision making.

Medical Necessity Criteria

Medical Necessity for Diagnostic Genetic Testing

Genetic testing to establish a genetic diagnosis of a mitochondrial disorder may be considered medically necessary when ALL of the following are met:

ALL of the following

Signs and symptoms of a mitochondrial disorder are present
Genetic testing may eliminate the need for muscle biopsy

Evidence and utility

Targeted Familial Variant Testing (Preconceptional Carrier Testing) in At-Risk Relatives

Targeted genetic testing for a known familial variant may be considered medically necessary when ALL of the following are met:

ALL of the following

A variant that is known to be pathogenic for that specific mitochondrial disorder has been identified in the index case
There is a defined mitochondrial disorder in the family of sufficient severity to cause impairment of quality of life or functional status

Evidence: Clinical validity is expected to be high for targeted testing of a known familial variant and testing may impact reproductive decision making when the familial disease is severe.

Covered Proprietary Laboratory Analyses (PLA)

The following PLA test may be considered medically necessary when the medical criteria above have been met:

Covered PLA: Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (Variantyx, Inc.) — CPT code 0417U

Proprietary PLA: whole mitochondrial genome sequencing with heteroplasmy detection and deletion analysis plus nuclear-encoded mitochondrial gene analysis of 335 genes.

Coding

Covered PLA code for Genomic Unity® Comprehensive Mitochondrial Disorders AnalysisHCPCSCovered

0417U

Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes (New Code Effective 10/01/2023)

Code effective date note: 0417U — New Code Effective 10/01/2023.

This PLA corresponds to the Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (Variantyx, Inc.), defined as whole mitochondrial genome sequencing with heteroplasmy detection and deletion analysis plus nuclear-encoded mitochondrial gene analysis of 335 nuclear genes.

Provider Actions

Prior Authorization

Prior Authorization Required for Medicare Advantage

Prior authorization is required for Medicare Advantage Plans for Genomic Unity® Comprehensive Mitochondrial Disorders Analysis (CPT 0417U). It is recommended for Commercial Products.

0417U
Recommended for Commercial Products

Documentation Required

Ordering Physician Must Handle Authorization and Appeals

Only the ordering physician shall be involved in the authorization, appeal, or other administrative processes related to prior authorization/medical necessity. Laboratories or third parties must not obtain authorization on behalf of the ordering physician; use of a laboratory representative or third party to obtain authorization or assist in appeals is prohibited and may result in termination from the provider network.

Labs and third parties must not obtain authorization on behalf of the ordering physician

Denial Risk

Unauthorized Laboratory Services Denied to Laboratory

If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

0417U
Service will be denied to the laboratory and may not be billed to the member

Background

Mitochondrial diseases are multisystem disorders caused by dysfunction of mitochondrial protein complexes and can result from pathogenic variants in either mitochondrial DNA (mtDNA) or numerous nuclear DNA (nDNA) genes. They preferentially affect high-energy organs (eg, central nervous system, heart, skeletal muscle) and have heterogeneous severity and overlapping syndromes, making diagnosis challenging.

Diagnostic challenges include nonspecific symptoms, overlapping clinical presentations, limited sensitivity and specificity of biochemical screening (eg, serum lactic acid), and that invasive testing such as muscle biopsy may be nondiagnostic or unnecessary if a genetic diagnosis can be obtained.

Testing strategies vary by suspected disorder and may include targeted testing for known point mutations, deletion/duplication analysis (eg, for CPEO and Kearns-Sayre), NGS panels of relevant nuclear genes, and whole mitochondrial genome sequencing with heteroplasmy detection; choice of test depends on the clinical context.

Studies of genetic testing in symptomatic individuals include case series and cohorts; for NGS panels the reported diagnostic yield is 15%–25%. Clinical specificity is not fully defined and some pathogenic variants can be found in the general population without disease, but overall clinical utility is relatively high when testing confirms a diagnosis and can obviate muscle biopsy.

For asymptomatic at-risk relatives, targeted testing of a known familial pathogenic variant has expected high clinical validity (with adequate analytic validity) and can affect reproductive decision making when the family disease is severe enough to cause impairment; evidence supports improved net health outcome for targeted familial testing.